



TB-CAD Access Agreements – DeepTek & Delft

AUGUST 2026

In July 2026, Unitaid and CHAI announced new access agreements with two leading providers of TB screening software: DeepTek and Delft Imaging. These agreements reduce the cost of CAD software in low- and middle-income countries through a low, annual fee package for CAD access. Below are answers to Frequently Asked Questions regarding the products and new access model.

For further information, please contact Claire Watkins, CHAI Global Markets Team,
calbert@clintonhealthaccess.org

Frequently Asked Questions

What is CAD and why is it important in screening programmes for TB?

Computer aided detection (CAD) is software that uses artificial intelligence to interpret chest X-ray images and identify abnormalities consistent with pulmonary TB, producing a score that indicates the likelihood that TB is present. The World Health Organization recommends CAD for TB screening and triage in individuals aged 15 and older. CAD is important because many high burden countries face a severe shortage of radiologists to interpret chest x-ray results, in some settings as few as one per million people. X-ray screening using CAD allows for timely screening to identify individuals requiring a diagnostic test for TB.

What products are covered under this agreement?

[Genki from DeepTek](#) and [CAD4TB from Delft Imaging](#) are the two CAD products offered under these new access terms. Both products are CE-certified and found to meet WHO performance standards for the use of CAD.¹

About Genki & DeepTek

DeepTek is a global leader in AI-powered radiology solutions, deployed across 2,000+ healthcare sites worldwide and touching a patient every five seconds. Founded by a radiologist and a technology entrepreneur, DeepTek has demonstrated AI adoption at scale, including national-level implementations in countries such as Singapore. Its chest X-ray AI solutions have received US FDA, CE, and regulatory clearances across 10+ countries and are widely used for TB screening globally. Trusted by governments, national TB programs, and global health organizations, DeepTek is helping expand access to high-quality lung health screening, particularly across LMICs. For more information, visit www.deeptek.ai.

Genki is a WHO-recommended CAD AI solution that analyzes digital chest X-rays within 30 seconds to support TB screening and detect 20+ pulmonary abnormalities in populations aged four years and above. It can operate offline and be deployed on existing X-ray workstations, often without

¹ [Use of computer-aided detection software for tuberculosis screening: WHO policy statement. Geneva: World Health Organization; 2025.](#)



additional hardware, making it well suited for scalable screening programs in remote and low-connectivity settings.

About CAD4TB & Delft

Delft Imaging develops and delivers diagnostic imaging solutions tailored to strengthen health systems in vulnerable and resource-constrained settings. Since 2002, the organization has supported healthcare programs with AI-enabled screening, digital X-ray, mobile clinics, point-of-care ultrasound, capacity building, and long-term service and support to improve patient outcomes across lung health and maternal health. To date, Delft Imaging solutions have supported screening for 55 million people across 90+ countries, with 3,000+ installations deployed and 4,300+ health professionals trained. For more information, visit www.delftimaging.com.

CAD4TB is a CE-certified CAD AI solution that analyses chest X-rays for people ages 4 and older and provides TB and abnormality scores, a radiological heatmap, and a cardiothoracic ratio for every exam. These outputs support clinical decision-making and program reporting.

What are the benefits of the new access pricing?

The access agreements set reduced pricing for 1- and 3-year access packages that includes training and installation, software updates, and service and maintenance. The agreements bring greater price transparency to the total cost of procuring TB CAD through more inclusive pricing packages that do not require separate service and support charges. Compared to previous 1-year plans priced at \$7,000 - \$12,000 per year for the CAD license alone, these packages represent an approximate 65% price reduction. They also lower the barrier to entry for programs interested in introducing and scaling TB CAD use. Compared to “perpetual” and multi-year licenses that required a \$10,000-\$20,000+ upfront investment, these plans reduce the initial investment for TB programs while also reducing the overall average annual cost by roughly 25-30%.

What is covered under the new access pricing?

The table below summarizes the access pricing and package inclusions from both suppliers.

Term	DeepTek Genki	Delft CAD4TB
Pricing / access fee	\$2,850 for 1-year commitment \$7,500 for 3-year commitment	\$2,500 for 1-year commitment \$7,500 for 3-year commitment
Product	Genki Edge v3.4.2 – offline and online access to the software for unlimited scans	CAD4TB v8.b.c – offline and online access to the software for unlimited scans
<i>Additional inclusions provided at no additional cost:</i>		
Training & installation	Remote installation and training, access to online training, and remote refresher trainings at no additional charge; On-site support available on request	Remote installation and training, access to online training, and remote refresher trainings at no additional charge; On-site support available on request for orders of 30+ units

Term	DeepTek Genki	Delft CAD4TB
Software updates	Software updates, patches, and security updates	Software updates, patches, and security updates
Service & Maintenance	Corrective maintenance and support – helpdesk access, spare parts, and remote preventive maintenance	Corrective maintenance and support – helpdesk access, spare parts, and remote preventive maintenance
Patient Management Platform	Access to DeepTek Augmento platform and dashboard for electronic patient registration, review of Genki results, access to patient and screening statistics, and adjustment to screening thresholds	Access to CAD4TB platform and dashboard for electronic patient registration, review of CAD4TB results, access to patient and screening statistics, and adjustment to screening thresholds

What infrastructure is required to deploy CAD?

CAD requires chest X-ray hardware to integrate with, as well as computing requirements for the software to run. **In many cases, the software can be deployed on the laptop already used for chest X-ray interpretation.**

DeepTek's Genki can run on existing laptop or workstation and no additional hardware is required as long as laptop or workstation meets the below specifications:

Recommended for TB+20 lung abnormalities	Recommended for TB only
- RAM: 32GB - Storage: 500GB - Processor: i5 or above	- RAM: 16GB - Storage: 500GB - Processor: i5 or above

Eligible buyers may get in touch with the suppliers to ascertain minimum infrastructure requirements for deploying CAD.

What are the hardware costs, if required?

Buyers will need to determine their hardware (e.g. laptop, box, tablet) requirement in consultation with the relevant CAD provider. CAD software can often be integrated on the laptop already in use with the chest X-ray unit and may not require additional hardware, provided the existing chest X-ray hardware meets the specifications required to run the software (see details above).

Where additional hardware is required, the following hardware terms and pricing apply:

Term	DeepTek	Delft
Price	\$2,499	\$2,500
Incoterm	DAP (Delivery at Place)	DAP (Delivery at Place)
Optional Hardware Inclusions	Edge Laptop and all product components and accessories necessary for efficient	CAD4TBbox (Mini PC), tablet, router, and external hard drive



Term	DeepTek	Delft
	application of Genki software and Augmento Platform	
Additional warranty extension	3-year warranty included at no additional charge	\$500 per year of additional warranty
<i>*Please reach out to CHAI or the suppliers for additional terms and warranty information</i>		

Are there any additional costs beyond the annual fee?

No additional costs apply for TB screening under the all-inclusive annual fee. Indications other than TB screening can be accessed for affordable add-on pricing. Pricing and add on indications for each provider are detailed in Annex 2.

Which countries are eligible to access these prices as per the negotiated agreement?

The agreements apply to all 138 World Bank defined low, lower-middle, and upper-middle-income countries, as defined by the World Bank at the time of this agreement. The full list of countries is provided in Annex 1.

Which buyers are eligible?

Public sector and not-for-profit buyers across the eligible countries may access this pricing. This includes agents procuring on behalf of these public sector or not-for-profit buyers.

What is the duration of this agreement?

This pricing agreement remains in effect through December 2029.

What is the difference between the one-year and three-year pricing terms?

Programs may select one year access, priced at \$2,500 to \$2,850 per connected X-ray unit, or a three-year term, priced at \$7,500 per connected X-ray unit, allowing procurement to be aligned with longer funding cycles. The newly negotiated yearly pricing provides flexibility to align procurements with budget planning cycles.

How can countries access this CAD software at the new reduced price?

The new pricing and terms are currently available directly from DeepTek and Delft Imaging. The companies are also working with the Stop TB Partnership's Global Drug Facility (GDF) and Global Fund PPM to enable purchasing through those channels. Delft's CAD4TB is currently available under different pricing packages from GDF and GF PPM.

Orders can also be placed directly with either supplier by reaching out to focal points -

DeepTek (Genki): globalhealth@deeptek.ai and Delft Imaging (CAD4TB): Myrto Allamani - mallamani@delftimaging.com

Can existing customers with older license agreements transition to the new pricing?

Yes. Countries with existing licenses may transition to the new annual pricing once their current license expires. Countries holding a perpetual license may also choose to move to the new annual



pricing instead of purchasing a separate software and maintenance (S&M) or warranty extension package.

Can this pricing be accessed for GC8 planning and procurement?

Yes. The pricing is now available for countries to procure and can therefore be used for GC8 planning and procurement.

Is pediatric CAD covered under this agreement?

The WHO currently does not recommend CAD for TB screening and triage for individuals below 15 years of age. DeepTek and Delft are both committed to working with WHO to evaluate their products for pediatric use and to provide access to pediatric CAD at no additional cost upon approval and recommendation.

Which chest X-ray systems is the CAD software compatible with?

Both CAD4TB and DeepTek's Genki are compatible with any chest X-ray system producing DICOM images.

Annex 1

Afghanistan	Ghana	Pakistan
Albania	Grenada	Panama
Algeria	Guatemala	Papua New Guinea
Angola	Guinea	Paraguay
Argentina	Guinea-Bissau	Peru
Armenia	Haiti	Philippines
Azerbaijan	Honduras	Romania
Bangladesh	India	Russian Federation
Belarus	Indonesia	Rwanda
Belize	Iran, Islamic Rep.	Samoa
Benin	Iraq	São Tomé and Príncipe
Bhutan	Jamaica	Senegal
Bolivia	Jordan	Serbia
Bosnia and Herzegovina	Kazakhstan	Sierra Leone
Botswana	Kenya	Solomon Islands
Brazil	Kiribati	Somalia
Bulgaria	Korea, Dem. People's Rep.	South Africa
Burkina Faso	Kosovo	South Sudan
Burundi	Kyrgyz Republic	Sri Lanka
Cabo Verde	Lao PDR	St. Lucia
Cambodia	Lebanon	St. Vincent and the Grenadines
Cameroon	Lesotho	Sudan
Central African Republic	Liberia	Suriname
Chad	Libya	Syrian Arab Republic
China	Madagascar	Tajikistan
Colombia	Malawi	Tanzania
Comoros	Malaysia	Thailand
Congo, Dem. Rep.	Maldives	Timor-Leste
Congo, Rep.	Mali	Togo
Costa Rica	Marshall Islands	Tonga
Côte d'Ivoire	Mauritania	Tunisia
Cuba	Mauritius	Turkey
Djibouti	Mexico	Turkmenistan
Dominica	Micronesia, Fed. Sts.	Tuvalu
Dominican Republic	Moldova	Uganda
Ecuador	Mongolia	Ukraine
Egypt, Arab Rep.	Montenegro	Uzbekistan
El Salvador	Morocco	Vanuatu
Equatorial Guinea	Mozambique	Venezuela, RB
Eritrea	Myanmar	Vietnam
Eswatini	Namibia	West Bank and Gaza
Ethiopia	Nepal	Yemen, Rep.
Fiji	Nicaragua	Zambia
Gabon	Niger	Zimbabwe
Gambia, The	Nigeria	
Georgia	North Macedonia	

Annex 2

DeepTek “Add-On” Indications

When purchasing through this access model, purchasers may choose to add additional indications and capabilities under the following pricing schedule:

1. **Clinical Conditions Group 1** (USD 0 additional charge): Any first five indications from the following EU CE MDR certified conditions: Opacity, Pneumonia, Atelectasis, Fibrosis, Cardiomegaly, Pleural Effusion, Pleural Thickening, Pneumothorax, Rib and Clavicular Fractures, Foreign Objects Detection.
2. **Clinical Conditions Group 2** (USD 90 per device per year): Next five indications from the following EU CE MDR certified conditions: Opacity, Pneumonia, Atelectasis, Fibrosis, Cardiomegaly, Pleural Effusion, Pleural Thickening, Pneumothorax, Rib and Clavicular Fractures, Foreign Objects Detection.
3. **Silicosis** - USD 90 per device
4. **Oncology Indications** (USD 180 per device per year): Two EU CE MDR certified conditions: Lung nodule detection, Lung mass identification.
5. **Foreign Objects Classification** (USD 180 per device per year): Classification of external or foreign objects commonly encountered on chest X-ray images (EU CE MDR Certified): Chest leads, Pacemaker, Spinal implant, Sternal sutures, Surgical clips, Central venous lines, Endotracheal tube, Nasogastric tube, Tracheostomy tube.

Delft Included Indications

When purchasing through this access model, purchasers will have access to the following additional indications at no additional cost:

1. **Silicosis** screening;
2. **Cardiomegaly** screening (EU CE MDR Certified); and
3. **General lung abnormality scoring** (EU CE MDR Certified), which provides an elevated CAD4TB abnormality score under a consolidated score where any of the following findings are identified on a chest X-ray: Pleural Effusion, Consolidation, Pleural Thickening, Lung Opacity, Emphysema, Nodule/Mass, Fibrosis, Atelectasis, Infiltration, and Pneumothorax